Forschung & Innovation
Publikationen
Effectiveness of the innovative Austrian phase III cardiac rehabilitation model on cardiovascular risk factors: a nationwide registry
PMU Autor*innen
Bernhard Reich, Gunnar Treff, Josef Niebauer
Alle Autor*innen
Bernhard Reich, Gunnar Treff, Andrea Podolsky, Heimo Traninger, Karl Mayr, Magdalena Wagner-Dauerböck, Silvia Wolfsteiner, Helmuth Ocenasek, Wolfgang Ziegelmeyer, Michael Porodko, Andreas Kriechhammer, Josef Niebauer
Fachzeitschrift
Open Heart
Kurzfassung
Introduction: The Austrian model of outpatient cardiac rehabilitation (CR) begins right after discharge from the acute care hospital. During phase II (OUT-II), it provides a facility-based, professionally supervised, multidisciplinary programme of 6 weeks. The subsequent, supervised phase III (OUT-III) lasts 6 months. In 2017, a 3-6 months lasting unsupervised home-based training has been added, which is followed by a 4-week facility-based evaluation and training period, called 'refresher'. We aimed to assess the effectiveness of this programme using a nationwide registry. Methods: Anthropometric data, resting blood pressure, lipid profile, maximum exercise capacity (P-max), anxiety (HADS-A) and depression (HADS-D) of all patients (n=1458) who participated in OUT-III between 1 January 2018 and 30 August 2022 were analysed. Data were assessed at the beginning of OUT-III (OUT-IIIstart), end of the supervised period (OUT-IIIend) and during the refresher (OUT-IIIrefresher). Results: From OUT-IIIstart to OUT-IIIend, P-max (155 +/- 1.4 W to 167 +/- 1.6 W; p<0.001) and high-density lipoprotein (HDL) increased (49 +/- 0.4 mg/dL to 51 +/- 0.4 mg/dL; p<0.001), low-density lipoprotein (LDL) decreased (82 +/- 1.0 mg/dL to 79 +/- 1.1 mg/dL; p<0.001), while total cholesterol (CHOL) remained statistically unchanged (150 +/- 43.3 mg/dL to 149 +/- 43 mg/dL; p<0.999). From OUT-IIIend to OUT-IIIrefresher, P-max slightly decreased (164 +/- 1.6 W; p<0.001), HDL further increased (52 +/- 0.5 mg/dL; p<0.020), whereas LDL (79 +/- 1.3 mg/dL; p<0.999) and CHOL remained unchanged (149 +/- 41 mg/dL; p<0.999).Anxiety (4.8 +/- 0.1 aU, 4.2 +/- 0.1 aU; p<0.001, 4.0 +/- 0.1 aU; p<0.001) and depression (3.7 +/- 0.1 aU, 34 +/- 0.1 aU; p<.001, 3.1 +/- 0.1 aU; p<0.001) continuously decreased from OUT-IIIstart to OUT-IIIend and the OUT-IIIrefresher. Conclusion: OUT-III CR resulted in sustained improvement in P-max, blood lipids, anxiety and depression.